The China Pulmonary Thromboembolism Registry Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

15000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Epidemiological data on pulmonary embolism (PE) in China needs to be updated and reported. The China Pulmonary Thromboembolism Registry Study (CURES) is designed to provide the cross-sectional spectrum and chronological trends of PE in China, as well as to reveal the intrinsic etiology and pathogenesis of the disease. The CURES is an ongoing large prospective multicenter registry, which was originally initiated in January 2009 via enrolling suspected or confirmed PE or PE with DVT (deep venous thrombosis) patients and assessed their in-hospital outcomes from 100 medical centers in the China PE-DVT network. As of July 2011, in order to determine the PE-relevant short-term outcomes, enrolled participants were followed-up for at least three months in a longitudinal manner. Since August 2016, with the launch and development of precision medicine research scheme in China, the main principle investigators of CURES decided to collect enrolled patients' blood samples with regular follow-ups every three or six months for at least two years (for long-term outcomes). The study protocol has been approved by the China-Japan Friendship Hospital ethics committee, and all collaborating centers received approvals from their local ethics committee. All patients provided written or verbal informed consent to their participation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Thrombolytic and Interventional Treatment of Pulmonary Embolism

NCT03886194

Pulmonary Embolism

UNKNOWN NA

Registry for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism in China

NCT03185377

COPD PTE - Pulmonary Thromboembolism

UNKNOWN

Epidemiological Study of Chronic Thromboembolic Pulmonary Hypertension in China

NCT01717092

To Assess the Long-term Risk for Adverse Events After PE.

UNKNOWN

Pulmonary Embolism Prognosis Model

NCT04411888

Pulmonary Embolism

UNKNOWN

Clinical Characteristics of Acute Pulmonary Embolism in Chinese Population

NCT02214043

Pulmonary Embolism

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Embolism Deep Venous Thrombosis Venous Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Objectively confirmed symptomatic PE or PE with DVT patients aged 18 years or above;
* Be able to provide written or verbal informed consent to participation.

Exclusion Criteria

* Younger than 18 years;
* Participation in a therapeutic clinical trial with an unknown drug;
* Inability for at least three-month follow-up since July 2011;
* Suspected PE or PE with DVT patients admitted to the hospital whereas without confirmed medical evidence;
* Patients with a history of PE or DVT readmitted to the hospital for examination or treatment however with no evidence of acute episode or recurrence;
* Withdrawal or lack of informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No